Mitochondrial dysfunctions in bladder cancer: Exploring their role as disease markers and potential therapeutic targets

Critical Reviews in Oncology/Hematology

Volumn 117, Issue , 2017, Pages 67-72

  Cormio, Antonella ^a   Sanguedolce, Francesca ^b   Musicco, Clara ^c   Pesce, Vito ^a   Calò, Giuseppe ^b   Bufo, Pantaleo ^b   Carrieri, Giuseppe ^b   Cormio, Luigi ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c CNR   (Italy)

Author keywords

Bladder cancer; Lon protease; Mitofusin 2; Molecular markers; mtDNA copy number; mtDNA mutations; TFAM

Indexed keywords

COMPLEMENTARY RNA; ENDOPEPTIDASE LA; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL RNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MITOFUSIN 2; RNA; TUMOR MARKER; UNTRANSLATED RNA; BIOLOGICAL MARKER;

BLADDER CANCER; BODY FLUID; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; COPY NUMBER VARIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; EARLY DIAGNOSIS; GENE MUTATION; GERMLINE MUTATION; HUMAN; POINT MUTATION; PREDICTIVE VALUE; PROTEIN EXPRESSION; REVIEW; SOMATIC MUTATION; ANIMAL; BLADDER TUMOR; COMPLICATION; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; PROGNOSIS;

ANIMALS; BIOMARKERS; DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 85030556062     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2017.07.001     Document Type: Review

References (58)

1. Attardi, G., Animal mitochondrial DNA: an extreme example of genetic economy. Int. Rev. Cytol. 93 (1985), 93–145.
2. Avcilar, T., Kirac, D., Ergec, D., Koc, G., Ulucan, K., Kaya, Z., Kaspar, E.C., Turkeri, L., Guney, A.I., Investigation of the association between mitochondrial DNA and p53 gene mutations in transitional cell carcinoma of the bladder. Oncol. Lett. 12 (2016), 2872–2879.
3. Bardella, C., Pollard, P., Tomlinson, I., SDH mutations in cancer. Biochim. Biophys. Acta 1807 (2011), 1432–1443.
4. Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R.G., Chiavarina, B., Frank, P.G., Flomenberg, N., Howell, A., Martinez-Outschoorn, U.E., Sotgia, F., Lisanti, M.P., Ketones and lactate ʻfuelʼ tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9 (2010), 3506–3514.
5. Brandon, M., Baldi, P., Wallace, D.C., Mitochondrial mutations in cancer. Oncogene 25 (2006), 4647–4662.
6. Brookes, P.S., Yoon, Y., Robotham, J.L., Anders, M.W., Sheu, S.S., Calcium, ATP and ROS: a mitochondrial love-hate triangle. Am J. Physiol Cell Physiol. 287 (2004), C817–C833.
7. Burzio, V.A., Villota, C., Villegas, J., Landerer, E., Boccardo, E., Villa, L.L., Martínez, R., Lopez, C., Gaete, F., Toro, V., Rodriguez, X., Burzio, L.O., Expression of a family of noncoding mitochondrial RNAs distinguishes normal from cancer cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 9430–9434.
8. Cadenas, E., Davies, K., Mitochondrial free radical generation, oxidative stress and aging. Free Radic. Biol. Med. 29 (2000), 222–230.
9. Chen, X., Butow, R.A., The organization and inheritance of the mitochondrial genome. Nat. Rev. Genet. 6 (2005), 815–825.
10. Chen, K.H., Guo, X., Ma, D., Guo, Y., Li, Q., Yang, D., Li, P., Qiu, X., Wen, S., Xiao, R.P., Tang, J., Dysregulation of HSG triggers vascular proliferative disorders. Nat. Cell Biol. 6 (2004), 872–883.
11. Cormio, A., Musicco, C., Gasparre, G., Cormio, G., Pesce, V., Sardanelli, A.M., Gadaleta, M.N., Increase in proteins involved in mitochondrial fission, mitophagy, proteolysis and antioxidant response in type I endometrial cancer as an adaptive response to respiratory complex I deficiency. Biochem. Biophys. Res. Commun.(July(8)), 2017, 10.1016/j.bbrc.2017.07.047.
12. Corrado, M., Scorrano, L., Campello, S., Mitochondrial dynamics in cancer and neurodegenerative and neuroinflammatory diseases. Int. J. Cell Biol., 2012, 2012, 729290.
13. Cruz-Bermúdez, A., Vicente-Blanco, R.J., Gonzalez-Vioque, E., Provencio, M., Fernández-Moreno Á, M., Garesse, R., Spotlight on the relevance of mtDNA in cancer. Clin. Transl. Oncol. 19 (2017), 409–418.
14. Dasgupta, S., Hoque, M.O., Upadhyay, S., Sidransky, D., Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res. 68 (2008), 700–706.
15. Dasgupta, S., Hoque, M.O., Upadhyay, S., Sidransky, D., Forced cytochrome B gene mutation expression induces mitochondrial proliferation and prevents apoptosis in human uroepithelial SV-HUC-1 cells. Int. J. Cancer 125 (2009), 2829–2835.
16. DeBalsi, K.L., Hoff, K.E., Copeland, W.C., Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases. Ageing Res. Rev. 33 (2017), 89–104.
17. DiMauro, S., Tanji, K., Bonilla, E., Pallotti, F., Schon, E.A., Mitochondrial abnormalities in muscle and other aging cells: classification, causes and effects. Muscle Nerve 26 (2002), 597–607.
18. Ellinger, J., Bastian, P.J., Ellinger, N., Kahl, P., Perabo, F.G., Büttner, R., Müller, S.C., von Ruecker, A., Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett. 264 (2008), 274–280.
19. Ellinger, J., Müller, D.C., Müller, S.C., Hauser, S., Heukamp, L.C., von Ruecker, A., Bastian, P.J., Walgenbach-Brunagel, G., Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol. Oncol.: Semin. Orig. Invest. 30 (2012), 509–515.
20. Fliss, M.S., Usadel, H., Caballero, L., Wu, M.R., Buta, S.M., Eleff, J., Jen, D., Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287 (2000), 2017–2019.
21. Gibellini, L., Pinti, M., Boraldi, F., Giorgio, V., Bernardi, P., Bartolomeo, R., Nasi, M., De Biasi, S., Missiroli, S., Carnevale, G., Losi, L., Tesei, A., Pinton, P., Quaglino, D., Cossarizza, A., Silencing of mitochondrial Lon protease deeply impairs mitochondrial proteome and function in colon cancer cells. FASEB J. 28 (2014), 5122–5135.
22. Gibellini, L., Pinti, M., Bartolomeo, R., De Biasi, S., Cormio, A., Musicco, C., Carnevale, G., Pecorini, S., Nasi, M., De Pol, A., Cossarizza, A., Inhibition of Lon protease by triterpenoids alters mitochondria and is associated to cell death in human cancer cells. Oncotarget 6 (2015), 25466–25483.
23. Gibellini, L., De Biasi, S., Nasi, M., Iannone, A., Cossarizza, A., Pinti, M., Mitochondrial proteases as emerging pharmacological targets. Curr. Pharm. Des. 22 (2016), 2679–2688.
24. Granados, J.B., Méndez, J.P., Feria-Bernal, G., García-García, E., Tejeda, M.E., Rojano-Mejía, D., Tapia, A., Canto, P., Association of a TFAM haplotype with aggressive prostate cancer in overweight or obese Mexican Mestizo men. Urol. Oncol., 1439, 2016, S1078.
25. Guney, A.I., Ergec, D.S., Tavukcu, H.H., Koc, G., Kirac, D., Ulucan, K., Javadova, D., Turkeri, L., Detection of mitochondrial DNA mutations in nonmuscle invasive bladder cancer. Genet. Test. Mol. Biomarkers 16 (2012), 672–678.
26. Jakupciak, J.P., Maragh, S., Markowitz, M.E., Greenberg, A.K., Hoque, M.O., Maitra, A., Barker, P.E., Wagner, P.D., Rom, W.N., Srivastava, S., Sidransky, D., O'Connell, C.D., Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer, 8, 2008, 285.
27. Jin, B., Fu, G., Pan, H., Cheng, X., Zhou, L., Lv, J., Chen, G., Zheng, S., Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma. Med. Oncol. 28 (2011), S373–S380.
28. Johns, D.R., Paternal transmission of mitochondrial DNA is (fortunately) rare. Ann. Neurol. 54 (2003), 422–424.
29. Kunkel, G.H., Chaturvedi, P., Tyagi, S.C., Mitochondrial pathways to cardiac recovery: TFAM. Heart Fail. Rev. 21 (2016), 499–517.
30. Kurita, T., Izumi, H., Kagami, S., Kawagoe, T., Toki, N., Matsuura, Y., Hachisuga, T., Kohno, K., Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer. Cancer Sci. 103 (2012), 239–244.
31. Landerer, L., Villegas, J., Burzio, V.A., Oliveira, L., Villota, C., Lopez, C., Restovic, F., Martinez, R., Castillo, O., Burzio, L.O., Nuclear localization of the mitochondrial ncRNAs in normal and cancer cells. Cell. Oncol. 34 (2011), 297–305.
32. Lightowlers, R.N., Chinnery, P.F., Turnbull, D.M., Howell, N., Mammalian mitochondrial genetics: heredity, heteroplasmy and disease. Trends Genet. 13 (1997), 450–455.
33. Liu, Y., Lan, L., Huang, K., Wang, R., Xu, C., Shi, Y., Wu, X., Wu, Z., Zhang, J., Chen, L., Wang, L., Yu, X., Zhu, H., Lu, B., Inhibition of Lon blocks cell proliferation, enhances chemosensitivity by promoting apoptosis and decreases cellular bioenergetics of bladder cancer potential roles of Lon as a prognostic marker and therapeutic target in bladder cancer. Oncotarget 5 (2014), 11209–11224.
34. Maitra, A., Cohen, Y., Gillespie, S.E.D., Mambo, E., Fukushima, N., Hoque, M.O., Shah, N., Goggins, M., Califano, J., Sidransky, D., Chakravarti, A., The human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res. 14 (2004), 812–819.
35. Massari, F., Ciccarese, C., Santoni, M., Iacovelli, R., Mazzucchelli, R., Piva, F., Scarpelli, M., Berardi, R., Tortora, G., Lopez-Beltran, A., Cheng, L., Montironi, R., Metabolic phenotype of bladder cancer. Cancer Treat. Rev. 45 (2016), 46–57.
36. Mishra, P., Chan, D.C., Metabolic regulation of mitochondrial dynamics. J. Cell Biol. 212 (2016), 379–387.
37. Mo, M., Peng, F., Wang, L., Peng, L., Lan, G., Yu, S., Roles of mitochondrial transcription factor A and microRNA-590-3p in the development of bladder cancer. Oncol. Lett. 6 (2013), 617–623.
38. Murphy, M.P., How mitochondria produce reactive oxygen species. Biochem. J. 417 (2009), 1–13.
39. Musicco, C., Cormio, A., Calvaruso, M.A., Iommarini, L., Gasparre, G., Porcelli, A.M., TimperioA, M., Zolla, L., Gadaleta, M.N., Analysis of the mitochondrial proteome of cybrid cells harbouring a truncative mitochondrial DNA mutation in respiratory complex I. Mol. Biosyst. 10 (2014), 1313–1319.
40. Nie, X., Li, M., Lu, B., Zhang, Y., Lan, L., Chen, L., Lu, J., Down-regulating overexpressed human Lon in cervical cancer suppresses cell proliferation and bioenergetics. PLoS One, 8, 2013, e81084.
41. Parrella, P., Seripa, D., Matera, M.G., Rabitti, C., Rinaldi, M., Mazzarelli, P., Gravina, C., Gallucci, M., Altomare, V., Flammia, G., Casalino, B., Benedetti-Panici, P.L., Fazio, V.M., Mutations of the D310 mitochondrial mononucleotide repeat in primary tumors and cytological specimens. Cancer Lett. 190 (2003), 73–77.
42. Picaud, S., Kavanagh, K.L., Yue, W.W., Lee, W.H., Muller-Knapp, S., Gileadi, O., Sacchettini, J., Oppermann, U., Structural basis of fumarate hydratase deficiency. J. Inherit. Metab. Dis. 34 (2011), 671–676.
43. Potter, M., Newport, E., Morten, K.J., The Warburg effect: 80 years on. Biochem. Soc. Trans. 44 (2016), 1499–1505.
44. Reznik, E., Miller, M.L., Yasin, S., Lu, E., Riaz, N., Sarungbam, J., Tickoo, S.K., Al-Ahmadie, H.A., Lee, W., Seshan, V.E., Ari Hakimi, A., Sander, C., Mitochondrial DNA copy number variation across human cancers. eLife, 5, 2016, e10769.
45. Rivas, A., Burzio, V., Landerer, E., Borgna, V., Gatica, S., Ávila, R., López, C., Villota, C., de laFuente, R., Echenique, J., Burzio, L.O., Villegas, J., Determination of the differential expression of mitochondrial long non-coding RNAs as a noninvasive diagnosis of bladder cancer. MC Urol., 12, 2012, 37.
46. Rossignol, R., Faustin, B., Rocher, C., Malgat, M., Mazat, J.P., Letellier, T., Mitochondrial threshold effects. Biochem. J. 370 (2003), 751–762.
47. Shakhssalim, N., Houshmand, M., Kamalidehghan, B., Faraji, A., Sarhangnejad, R., Dadgar, S., Mobaraki, M., Rosli, R., Sanati, M.H., The mitochondrial C16069T polymorphism, not mitochondrial D310 (D-loop) mononucleotide sequence variations, is associated with bladder cancer. Cancer Cell Int. 13 (2013), 120–126.
48. Toki, N., Kagami, S., Kurita, T., Kawagoe, T., Matsuura, Y., Hachisuga, T., Matsuyama, A., Hashimoto, H., Izumi, H., Kohno, K., Expression of mitochondrial of transcription factor A in endometrial carcinomas: clinic-pathologic correlations and prognostic significance. Virchows Arch. 456 (2010), 387–393.
49. van Gisbergen, M.W., Voets, A.M., Starmans, M.H., de Coo, I.F., Yadak, R., Hoffmann, R.F., Boutros, P.C., Smeets, H.J., Dubois, L., Lambin, P., How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. Mutat. Res. Rev. Mutat. Res. 764 (2015), 16–30.
50. Wada, T., Tanj, N., Ozawa, A., Wang, J., Shimamoto, K., Sakayama, K., Yokoyama, M., Mitochondrial DNA mutations and 8-hydroxy-2′-deoxyguanosine content in Japanese patients with urinary bladder and renal cancers. Anticancer Res. 26 (2006), 3403–3408.
51. Wang, W., Lu, J., Zhu, F., Wei, J., Jia, C., Zhang, Y., Zhou, L., Xie, H., Zheng, S., Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells. Med. Oncol. 29 (2012), 70–76.
52. Warburg, O., On respiratory impairment in cancer cells. Science 124 (1956), 269–270.
53. Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., Rabinowitz, J.D., Carroll, M., Su, S.M., Sharp, K.A., Levine, R.L., Thompson, C.B., The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17 (2010), 225–234.
54. Williams, S.B., Ye, Y., Huang, M., Chang, D.W., Kamat, A.M., Pu, X., Dinney, C.P., Wu, X., Mitochondrial, DNAcontent as risk factor for bladder cancer and its association with mitochondrial DNA polymorphisms. Cancer Prev. Res. (Phila) 8 (2015), 607–613.
55. Wu, K., Zhao, Z., Xiao, Y., Peng, J., Chen, J., He, Y., Roles of mitochondrial transcription factor A and microRNA-590-3p in the development of colon cancer. Mol. Med. Rep. 14 (2016), 5475–5480.
56. Yoo, J.H., Suh, B., Park, T.S., Shin, M.G., Choi, Y.D., Lee, C.H., Choi, J.R., Analysis of fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection of early bladder cancer. Cancer Genet. Cytogenet. 198 (2010), 107–117.
57. Yoshida, Y., Hasegawa, J., Nezu, R., Kim, Y.K., Hirota, M., Kawano, K., Izumi, H., Kohno, K., Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX. Cancer Sci. 102 (2011), 578–582.
58. Zhang, G.E., Jin, H.L., Lin, X.K., Chen, C., Liu, X.S., Zhang, Q., Yu, J.R., Anti-tumor effects of mfn2 in gastric cancer. Int. J. Mol. Sci. 14 (2013), 13005–13021.